Bml Capital Management, LLC An2 Therapeutics, Inc. Call Options Transaction History
Bml Capital Management, LLC
- $170 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ANTX
# of Institutions
49Shares Held
25.2MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA5.55MShares$6.11 Million0.18% of portfolio
-
Octagon Capital Advisors LP New York, NY3.22MShares$3.54 Million1.6% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA2.09MShares$2.3 Million0.26% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$1.71 Million0.5% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.55MShares$1.71 Million0.0% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $21.3M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...